This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Tranche Update on Zhejiang Hisun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on December 23, 2023. CI
Zhejiang Hisun Pharmaceutical Co., Ltd.'s Equity Buyback announced on December 23, 2023, has closed with 11,687,200 shares, representing 0.98% for CNY 98.99 million. CI
Hisun Pharma's Unit Gets Nod for Pig Vaccine MT
Tranche Update on Zhejiang Hisun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on December 23, 2023. CI
China Energy Engineering Issues Apology Over Former Director's Stake Disposal Breaches MT
Tranche Update on Zhejiang Hisun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on December 23, 2023. CI
Zhejiang Hisun Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 100 million worth of its shares. CI
Zhejiang Hisun Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Gogox Holdings Chairman Steps Down MT
Hisun Pharmaceutical's Unit Gets Certification for Imported Drug from Pfizer MT
Hisun Pharmaceutical CFO Resigns MT
Hisun Pharmaceutical's Unit Gets Import Drug Certificate for Methylprednisolone Tablets MT
Hisun Pharmaceutical's Unit Gets Nod for Carprofen Tablets for Dogs MT
Hisun Pharma Registers New Veterinary Drug MT
Zhejiang Hisun Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Hisun Pharmaceutical Gets China Nod to Market Cytarabine MT
Tranche Update on Zhejiang Hisun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on September 22, 2022. CI
Zhejiang Hisun Pharmaceutical Co., Ltd.'s Equity Buyback announced on September 22, 2022, has closed with 18,489,100 shares, representing 1.55% for CNY 194.73 million. CI
Zhejiang Hisun Pharmaceutical Co., Ltd.(XSSC:600267) added to S&P Global BMI Index CI
Zhejiang Hisun Pharmaceutical Co., Ltd.(XSSC:600267) added to FTSE All-World Index CI
Shanghai Shyndec Pharma Gets Nod to Market Blood Sugar Drug Ingredient MT
Hisun Pharma Unit Gets Nod to Produce Apremilast API MT
Hisun Pharma Chairman, Vice Chairman Resign MT
Hisun Biomaterials Chairman Resigns MT
Zhejiang Hisun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Chart Zhejiang Hisun Pharmaceutical Co., Ltd.
More charts
Zhejiang Hisun Pharmaceutical Co., Ltd. is a China-based company, principally engaged in the research and development, manufacture and distribution of specialty bulk pharmaceutical chemicals and preparation products. The Company's bulk pharmaceutical chemicals mainly include antineoplastic drugs, cardiovascular drugs, anti-infection drugs, endocrine control drugs, anthelmintic, as well as animal remedies, among others. The Company is also engaged in the sales of drugs manufactured by other companies. The Company distributes its products in domestic markets and to overseas markets.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
7.64 CNY
Average target price
7.4 CNY
Spread / Average Target
-3.14%
Consensus
  1. Stock Market
  2. Equities
  3. 600267 Stock
  4. News Zhejiang Hisun Pharmaceutical Co., Ltd.
  5. Guangdong Tengen Industrial CFO Resigns; Successor Named